带状疱疹后神经痛治疗市场报告：2031 年趋势、预测与竞争分析

全球带状疱疹后神经痛治疗市场前景光明，医院药局、线上药局和零售药局市场都蕴藏着巨大的机会。预计2025年至2031年期间，全球带状疱疹后神经痛治疗市场的复合年增长率将达到4.0%。该市场的主要驱动力包括带状疱疹发病率的上升、人们对带状疱疹后神经痛认识的不断加深以及先进治疗方案的日益普及。

• Lucintel 预测，在类型类别中，抗惊厥药物预计在预测期内将出现更高的增长。
• 在应用类别中，零售药局预计将见证最高的成长。
• 从地区来看，预计北美将在预测期内实现最高成长。

带状疱疹后神经痛治疗市场的新趋势

带状疱疹后神经痛治疗市场正在见证一些新兴趋势，这些趋势正在彻底改变患者的照护和治疗。这些趋势涵盖技术进步、患者行为和治疗模式的改变等诸多面向。随着全球带状疱疹后神经痛 (PHN) 发病率的不断上升，这些趋势正在影响市场的发展方向，并为市场扩张和成长提供新的途径。

• 远距医疗整合：远距医疗也是带状疱疹后神经内科 (PHN) 管理的快速成长趋势，尤其是在远端监控和疼痛管理方面。随着线上医疗平台的普及，患者现在可以在家中舒适地与专家远距会面，而无需亲自到场就诊。对于农村或医疗资源匮乏地区的患者来说，远距医疗是一种经济实惠且便利的解决方案。
• 个人化医疗：个人化医疗在带状疱疹后神经痛 (PHN) 管理中发挥着日益重要的作用，使医疗保健专业人员能够根据患者的个别基因图谱、病史和具体需求制定个人化治疗方案。实施基因组检测和创建精准医疗疗法的趋势日益增长，正在彻底改变带状疱疹后神经痛 (PHN) 的管理。个人化策略正在帮助临床医生选择最佳治疗方案，从而改善患者预后并最大限度地减少副作用。
• 再生医学：再生医学疗法，包括干细胞疗法和组织再生，正在被探索作为带状疱疹后神经痛（PHN）的可能疗法。这些疗法旨在修復神经损伤并恢復正常功能，从而可能为带状疱疹后神经痛（PHN）患者带来长期缓解。该方向的研究尚处于起步阶段，但人们预计在不久的将来彻底改变带状疱疹后神经痛（PHN）的治疗。
• 联合疗法：联合疗法是指药物疗法和非药物疗法相结合的疗法，作为治疗带状疱疹后神经痛 (PHN) 的有效方法，正日益受到重视。透过口服药物与局部疗法、神经刺激装置或物理治疗的结合，患者的疼痛得到有效缓解，生活品质得到提升。随着医疗机构寻求为带状疱疹后神经痛 (PHN) 患者提供更全面的护理，对多模式治疗的日益关注正在推动市场成长。
• 非处方药 (OTC)：非处方 PHN 药物的研发势头日益强劲，患者无需就医即可治疗轻微症状。 OTC 乳膏、贴片和口服药物因其便利性和价格实惠而日益流行。这种自我用药的趋势在医疗保健资源匮乏的市场尤其重要。

这些新趋势正在改变带状疱疹后神经痛治疗市场，提升了治疗的可及性，扩大了治疗选择，并为患者提供更个人化的照护。数位化工具的使用、再生医学的扩展以及联合疗法的实施，正在带来更有效率、更有效的治疗方案。随着这些趋势的不断发展，带状疱疹后神经痛（PHN）的治疗模式可能会发生重大变化，为患者带来更好的治疗效果，并为市场创造新的成长机会。

带状疱疹后神经痛治疗市场的最新发展

近年来，带状疱疹后神经痛治疗市场经历了巨大的成长。由于该疾病仍然影响着全球数百万患者，新的治疗方法和发展不断涌现，从而带来了更好的护理和管理。製药公司和研究人员正致力于开发新的治疗方法，以提高疗效和患者预后。在新药上市、尖端技术和改进的治疗方法的推动下，市场正在经历转型，以缓解带状疱疹后神经痛（PHN）特有的残疾疼痛。

• 药物研发进展：近年来，带状疱疹后神经痛的新药研发取得了显着进展。辣椒素贴片和长效阿片类药物等新药的问世，显着改变了带状疱疹后神经痛的治疗。这些药物旨在持续缓解疼痛，副作用较少，从而提高患者的生活品质。对新型药物输送系统的研究不断加强，也有望提高治疗效果。
• 非鸦片类疼痛疗法的兴起：非鸦片类疗法作为一种比鸦片类药物更安全的带状疱疹后神经痛（PHN）治疗方案，正日益受到青睐。利多卡因、加巴喷丁和普瑞巴林等药物已被证明能有效缓解神经痛，且无鸦片类药物的危害。由于对阿片类药物依赖性和副作用的担忧，市场对这些疗法的接受度正在增长，这推动了对非阿片类疗法的需求。
• 远距医疗与治疗方案的整合：远距医疗极大地改变了带状疱疹后神经痛（PHN）的治疗。远距医疗平台如今已被广泛用于提供远距会诊，使患者能够更好地管理自体病情。这不仅拓宽了医疗服务管道，尤其惠及农村地区或医疗资源匮乏的患者，也方便了患者病情的监测和治疗方案的即时调整。
• 神经调节技术的进展：神经调节疗法，包括经颅磁刺激 (TMS) 和脊髓刺激，已在治疗带状疱疹后神经痛 (PHN) 方面显示出良好的疗效。这些疗法透过改变神经活动来减轻疼痛感知。随着这些技术日益精细化和微创化，它们正被整合到治疗方案中，为患者在传统药物治疗无效时提供替代疗法。
• 个人化医疗策略：个人化医疗日益受到重视，这有助于根据患者个体情况量身定制带状疱疹后神经性神经痛 (PHN) 治疗方案。基因研究的突破使临床医生能够根据患者的基因组成选择最佳治疗方案。这使得治疗方案更加精准高效，从而增强疼痛缓解效果并减少副作用。

这些进展正在彻底改变带状疱疹后神经痛的治疗方案，为患者提供更有效率、更安全、更个人化的治疗方案。新的治疗方法和创新正在增强带状疱疹后神经痛（PHN）的整体管理，减轻那些曾经几乎没有其他选择的患者所遭受的痛苦。这些进步也代表了医疗保健领域朝着非阿片类药物、个人化、技术驱动的解决方案发展的大趋势，这些解决方案兼顾了疗效和患者福祉。

目录

第一章：执行摘要

第二章：全球带状疱疹后神经痛治疗市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章：2019年至2031年市场趋势及预测分析

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球带状疱疹后神经痛治疗市场趋势（2019-2024 年）及预测（2025-2031 年）
• 全球带状疱疹后神经痛治疗市场（按类型）
  • 抗惊厥药
  • 皮肤贴片
  • 其他
• 全球带状疱疹后神经痛治疗市场（按应用）
  • 医院药房
  • 网路药局
  • 零售药局

第四章：2019 年至 2031 年各地区市场趋势及预测分析

• 全球带状疱疹后神经痛治疗市场（按地区）
• 北美带状疱疹后神经痛治疗市场
  • 北美市场类型：抗惊厥药、皮肤贴片及其他
  • 北美市场按应用划分：医院药房、网路药房和零售药房
• 欧洲带状疱疹后神经痛治疗市场
  • 欧洲市场类型：抗惊厥药、皮肤贴片及其他
  • 欧洲市场按应用划分：医院药房、网路药房和零售药房
• 亚太地区带状疱疹后神经痛治疗市场
  • 亚太地区市场类型：抗惊厥药、皮肤贴剂及其他
  • 亚太地区市场按应用划分：医院药房、网路药房和零售药房
• 其他带状疱疹后神经痛治疗市场
  • 其他市场类型：抗惊厥药、皮肤贴片及其他
  • 其他市场（按应用划分）：医院药房、网路药房和零售药房

第五章：竞争对手分析

• 产品组合分析
• 营运整合
• 波特五力分析

第六章：成长机会与策略分析

• 成长机会分析
  • 全球带状疱疹后神经痛治疗市场按类型分類的成长机会
  • 全球带状疱疹后神经痛治疗市场的成长机会（按应用）
  • 全球带状疱疹后神经痛治疗市场各区域的成长机会
• 全球带状疱疹后神经痛治疗市场的新趋势
• 战略分析
  • 新产品开发
  • 全球带状疱疹后神经痛治疗市场产能扩张
  • 全球带状疱疹后神经痛治疗市场的合併、收购和合资企业
  • 认证和许可

第七章：主要参与者的公司简介

• Pfizer
• Arbor Pharma
• Assertio Therapeutics
• Endo Pharma
• Teikoku Pharma
• Teva
• Mylan

The future of the global post herpetic neuralgia treatment market looks promising with opportunities in the hospital pharmacy, online pharmacy, and retail pharmacy markets. The global post herpetic neuralgia treatment market is expected to grow with a CAGR of 4.0% from 2025 to 2031. The major drivers for this market are the rising incidence of shingles, the growing awareness of post-herpetic neuralgia, and the increasing availability of advanced treatment options.

• Lucintel forecasts that, within the type category, anticonvulsant is expected to witness higher growth over the forecast period.
• Within the application category, retail pharmacy is expected to witness the highest growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.

Emerging Trends in the Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market is witnessing some emerging trends that are revolutionizing patient care and treatment. These trends vary from technological advancements to changes in patient behavior and treatment paradigms. With an increasing incidence of PHN across the globe, these trends are influencing the path of the market and presenting new avenues for expansion and growth.

• Telemedicine Integration: Telemedicine is also a fast-growing trend for PHN management, particularly for remote monitoring and pain management. As online health platforms proliferate, patients can now remotely meet with specialists in the comfort of their own homes without requiring in-person consultations. Telemedicine is an affordable and convenient solution for patients in rural or underserved locations.
• Personalized Medicine: Personalized medicine is increasingly playing a vital role in the management of PHN, enabling healthcare professionals to customize therapies in accordance with the patient's individual genetic profiles, history, and precise needs. The increasing trend of implementing genomic testing and creating precision medicine therapies is revolutionizing PHN management. Personalized strategies are assisting clinicians in the selection of the best treatments, thereby enhancing patient outcomes and minimizing side effects.
• Regenerative Medicine: Regenerative medicine treatments, including stem cell therapy and tissue regeneration, are being explored as possible PHN therapies. These treatments seek to heal nerve injury and restore normal function, which might provide long-term relief for PHN sufferers. Studies in this direction are in nascent stages, but there is hope that regenerative therapies will revolutionize the treatment of PHN in the near future.
• Combination Therapies: Combination therapies, involving a combination of pharmacological and non-pharmacological therapies, are picking up steam as effective approaches to treating PHN. With the combination of oral drugs and topical therapies, nerve stimulation devices, or physical therapy, patients show improved pain relief and enhanced quality of life. The growing focus on multi-modal treatments is fueling market growth as providers seek to provide more holistic care to PHN patients.
• Over-the-Counter (OTC) Products: There is increasing momentum in the creation of over-the-counter PHN drugs so that patients can treat minor symptoms without seeing a doctor. OTC creams, patches, and oral medications are becoming popular due to convenience and affordability. This trend toward self-medication is particularly critical in markets where access to health care is restricted.

These new trends are transforming the post herpetic neuralgia treatment market by enhancing accessibility, expanding treatment options, and offering more individualized care to patients. The use of digital tools, the expansion of regenerative medicine, and the implementation of combination therapies are leading to more efficient and effective treatments. As these trends continue to evolve, the treatment landscape for PHN will likely undergo significant changes, offering better outcomes for patients and creating new opportunities for growth in the market.

Recent Developments in the Post Herpetic Neuralgia Treatment Market

The post herpetic neuralgia treatment market has witnessed massive growth in the recent past years. With the condition still impacting millions of patients globally, new treatments and developments are coming into view, resulting in better care and management. Drug firms as well as researchers are concentrating on new treatment methodologies, enhancing efficacy, and patient outcomes. The market is experiencing transformation fueled by novel drug launches, cutting-edge technologies, and improved therapeutic approaches to alleviate the disabling pain that characterizes PHN.

• Progress in Drug Development: In the last few years, there has been substantial advancement in the new drug development for Post-Herpetic Neuralgia. The introduction of new drugs such as capsaicin patches and long-acting opioids has significantly changed the treatment of PHN. These drugs target sustained relief from pain with less side effect, enhancing the quality of life in patients. Increased research into new drug delivery systems also holds the potential for enhancing treatment effectiveness.
• Emergence of Non-Opioid Pain Therapies: Non-opioid therapies are gaining momentum as a more secure option than opioid-based treatments for PHN. Drugs such as lidocaine, gabapentin, and pregabalin proved effective in alleviating nerve pain without the hazards of opioids. The market is experiencing growth in the acceptance of these therapies due to fears of opioid dependency and side effects fueling demand for non-opioid therapies.
• Telemedicine Integration in Treatment Plans: Telemedicine has transformed the treatment of PHN dramatically. Telemedicine platforms are now widely utilized to offer remote consultations, enabling patients to better manage their condition. This has opened up access to healthcare, particularly for rural or underserved patients, and has facilitated easier monitoring of patient progress and real-time adjustment of treatments.
• Advances in Neuromodulation Techniques: Neuromodulation therapies, including transcranial magnetic stimulation (TMS) and spinal cord stimulation, have shown promising results in treating PHN. These therapies work by altering nerve activity to reduce pain perception. As these techniques become more refined and less invasive, they are being integrated into treatment regimens, offering patients alternatives when traditional medications fail.
• Personalized Medicine Strategy: The growing emphasis on personalized medicine is assisting in tailoring PHN therapies to the individual. Breakthroughs in genetic research are making it possible for clinicians to select the most optimal therapies according to a patient's genetic makeup. This enables more precise and efficient treatment regimens, resulting in enhanced pain relief and reduced side effects.

These advancements are revolutionizing the post herpetic neuralgia treatment scenario by providing patients with more efficient, safer, and customized options. New treatments and innovations are enhancing the overall management of PHN, alleviating suffering for those who once had few alternatives. These advancements also represent a larger trend within the healthcare sector towards non-opioid, customized, and technology-driven solutions that balance both efficacy and patient welfare.

Strategic Growth Opportunities in the Post Herpetic Neuralgia Treatment Market

Post herpetic neuralgia treatment market is witnessing a number of growth prospects fueled by innovations, technological breakthroughs, and growing demand for improved solutions. The market is growing as increasing targeted therapies, developments in the mode of delivery of treatments, and growing emphasis on patient-centric care are providing opportunities to grow. Pharmaceutical organizations, healthcare providers, and investors are looking into major applications that will improve treatment and patient outcomes.

• Innovations in Topical Therapies: Topical therapies, including lidocaine and capsaicin patches, are emerging as a major growth opportunity in the PHN market. These treatments deliver localized pain relief with few systemic side effects and are thus a desirable choice for patients who want alternatives to oral drugs. Ongoing innovations in formulation and delivery systems will increase the efficacy and market penetration of topical therapies.
• Growth of Non-Opioid Therapeutics: With increasing need for non-opioid treatment of pain, there is evidently a chance of developing drugs which address the basic mechanisms of PHN without opioid dependency. Emerging molecules like newer anticonvulsants and antidepressants are being researched for better control of nerve pain and provide a new growth opportunity for pharmaceutical companies.
• Telemedicine and Remote Monitoring Solutions: Expansion of telemedicine and digital health technologies is providing opportunities to enhance patient care and treatment outcomes for PHN. Remote monitoring devices, wearable sensors, and mobile health apps can monitor symptoms and modify treatments in real time. This enhances the convenience and accessibility of PHN care, particularly for patients who live in remote locations or have mobility problems.
• Enhanced Neuromodulation Devices: The neuromodulation device market, including spinal cord stimulators and peripheral nerve stimulators, is likely to grow substantially. These devices provide a non-pharmacologic treatment option for PHN and are becoming increasingly popular due to their efficacy and decreased side-effect profile. Increased research and development will further enhance these devices, making them more precise and patient beneficial.
• Personalized Medicine in Pain Relief: Personalized medicine offers a sizeable growth opportunity through the targeting of treatments with genetic and molecular patient profiling. This strategy should maximize pain relief for PHN patients, so that the correct treatments are used for each. The incorporation of genomic information into treatment plans will enhance efficacy and reduce side effects, making personalized therapies a central market driver.

These growth opportunities reflect the trend towards more personalized, non-opioid, and technology-based solutions in the management of post herpetic neuralgia. As these applications mature, they not only enhance patient outcomes but also increase the scope of available treatment options. This makes the market more competitive and diverse, with increased emphasis on patient-centric care, which will fuel market growth in the next few years.

Post Herpetic Neuralgia Treatment Market Driver and Challenges

The post herpetic neuralgia treatment market is driven by a wide range of factors involving technology advancements, economic factors, and regulatory forces. Although many drivers are dominating the growth of the market, some obstacles such as regulatory barriers and treatment constraints are also affecting the rate of growth. Knowledge of these drivers and challenges is essential for stakeholders to steer the changing landscape of PHN treatment successfully.

The factors responsible for driving the post herpetic neuralgia treatment market include:

1. Growing Incidence of Herpes Zoster: One of the key drivers of demand for PHN treatments is the growing incidence of Herpes Zoster (shingles). With the aging of the global population, the number of cases of shingles and its complications, such as PHN, is on the rise. This is fueling the demand for effective treatments and therapies, leading to the expansion of the PHN treatment market.

2. Technological Advances in Treatment Modalities: The quick developments in neuromodulation technologies, customized medicine, and drug delivery devices are having a positive impact on the PHN treatment market. The new developments are making treatments more precise and effective, enhancing patient outcomes, and driving market growth. R&D is being heavily invested in by companies to introduce advanced technologies to the market.

3. Increased Awareness and Rising Diagnosis Rates: Public awareness regarding PHN and its effect on the quality of life of patients has increased over time. Increasing awareness is resulting in early diagnosis and treatment, which is fueling the demand for therapeutic solutions. Physicians are also learning to identify PHN at an early stage, further contributing to market growth.

4. Demand for Non-Opioid Pain Management: Owing to increasing fears over opioid addiction and dependence, demand for non-opioid pain management practices has picked up quite well. Increasing need for substitute treatment methods providing potent pain relief with minimal potential for addiction is pushing the usage of non-opioid treatment in PHN, stimulating the market growth.

5. Government Programs and Funding: Governments globally are realizing the cost of chronic pain conditions such as PHN, and many are providing incentives and funding to stimulate research on new treatments. This funding is stimulating innovation and speeding up the creation of better therapies.

Challenges in the post herpetic neuralgia treatment market are:

1. Regulatory and Approval Delays: One of the biggest challenges in the PHN treatment market is the long and complex approval process for emerging therapies. Delays in regulation can hinder the timely release of new and innovative therapies, limiting market growth and patient access to leading-edge therapies.

2. Limited Efficacy of Current Therapies: Although a variety of PHN treatments are currently available, patients still suffer from inadequate pain relief. The failure of universally effective therapies is one of the biggest challenges, and as a result, drug treatments fall short, creating unmet medical needs and ongoing demand for more effective treatments.

3. Cost of Treatment: The expensive nature of some PHN treatments, especially advanced neuromodulation equipment and customized therapies, continues to be a barrier for most patients. In other areas, insufficient insurance coverage and budgetary issues deter patients from obtaining the best treatment, which influences market adoption levels.

The post herpetic neuralgia market for treatment is expanding through rising incidence, technological innovation, and transition to pain management through non-opioid options. Despite these, limitations such as slow regulatory processes, limited effectiveness of existing therapies, and high costs of treatment are currently major impediments. Addressing these through innovation, changes in regulations, and enhanced affordability will be essential to further growth in the market and the creation of more effective PHN treatments.

List of Post Herpetic Neuralgia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies post herpetic neuralgia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the post herpetic neuralgia treatment companies profiled in this report include-

• Pfizer
• Arbor Pharma
• Assertio Therapeutics
• Endo Pharma
• Teikoku Pharma
• Teva
• Mylan

Post Herpetic Neuralgia Treatment Market by Segment

The study includes a forecast for the global post herpetic neuralgia treatment market by type, application, and region.

Post Herpetic Neuralgia Treatment Market by Type [Value from 2019 to 2031]:

• Anticonvulsants
• Skin Patch
• Other

Post Herpetic Neuralgia Treatment Market by Application [Value from 2019 to 2031]:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Post Herpetic Neuralgia Treatment Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Post Herpetic Neuralgia Treatment Market

In recent years, the post herpetic neuralgia treatment market has seen considerable growth in different countries like the United States, China, Germany, India, and Japan. The market has been driven by the growth in both pharmaceuticals and other treatments that address the chronic pain of PHN. Major growth drivers of this market include an aging population, greater knowledge about PHN, and innovation in new drugs and technologies. Challenges in the availability of treatment, cost, and regulatory barriers continue, specifically in developing countries. Technological advancements and changing patient requirements are both influencing the growth of the market.

• United States: The United States is still a dominant force in the post herpetic neuralgia Treatment Market, led by developments in pain management therapies. New approvals of drugs, especially new analgesics and nerve-directed treatments, have increased the range of treatments available to patients. The U.S. is also still at the forefront of the use of transcutaneous electrical nerve stimulation (TENS) devices and other non-pharmacological therapies. Furthermore, the growing incidence of herpes zoster infections and heightened awareness of PHN have also stimulated demand for therapies. Healthcare infrastructure and insurance for such treatments also boost market growth in the region.
• China: The post herpetic neuralgia Treatment Market in China is increasing at a rapid pace due to a growing healthcare industry and heightened awareness of PHN. The Chinese government has been enhancing healthcare access, which is predicted to increase the uptake of treatments. Access to sophisticated pain treatment, though, is still challenging in rural China. While drugs rule the marketplace, traditional Chinese medicine (TCM) therapy is being added to treatment plans more and more, with expanding interest in herbal and acupuncture therapies. This blend of conventional and new medicine is anticipated to be instrumental in the development of the market.
• Germany: Germany's post herpetic neuralgia Treatment Market is helped by its highly developed healthcare system and strong pharmaceutical sector. There has been an increase in new drug approvals and availability that help ease PHN pain, including topical and anticonvulsant medications. Germany also places significant emphasis on pain management research, leading to the establishment of non-invasive therapies such as neuromodulation and TENS devices. With the increasing population of the elderly, the need for good PHN treatments is bound to be on the rise. The robust healthcare base also provides improved access to these treatments, fueling market growth.
• India: India is confronted with an upsurge in PHN prevalence, mainly caused by a rise in shingles. The healthcare system of the country has been changing very fast, and treatment for PHN is now more accessible. Affordability is a major issue still, especially in rural India. New trends in the Indian market are the launch of generic forms of newer pain management medications, which have made these treatments affordable. In addition, campaigns regarding PHN and its treatment are picking pace, which may result in more patient interaction and treatment compliance, hence further driving market growth.
• Japan: Japan has a robust healthcare infrastructure, and the treatment scenario for post herpetic neuralgia is progressing steadily. Japan's market has experienced a rise in the use of sophisticated pain management therapies, such as nerve-blocking therapy and the use of technology in pain management. Japan also takes the lead in conducting research into novel drug therapy for PHN, with emphasis on efficacy and safety. The government has been initiating a move to get these drugs more widely available to the elderly, so that effective pain management is accessible to the increasing population of PHN patients.

Features of the Global Post Herpetic Neuralgia Treatment Market

Market Size Estimates: Post herpetic neuralgia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Post herpetic neuralgia treatment market size by type, application, and region in terms of value ($B).

Regional Analysis: Post herpetic neuralgia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the post herpetic neuralgia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the post herpetic neuralgia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the post herpetic neuralgia treatment market by type (anticonvulsants, skin patch, and other), application (hospital pharmacies, online pharmacies, and retail pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Post Herpetic Neuralgia Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Post Herpetic Neuralgia Treatment Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Post Herpetic Neuralgia Treatment Market by Type
  • 3.3.1: Anticonvulsants
  • 3.3.2: Skin Patch
  • 3.3.3: Other
• 3.4: Global Post Herpetic Neuralgia Treatment Market by Application
  • 3.4.1: Hospital Pharmacies
  • 3.4.2: Online Pharmacies
  • 3.4.3: Retail Pharmacies

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Post Herpetic Neuralgia Treatment Market by Region
• 4.2: North American Post Herpetic Neuralgia Treatment Market
  • 4.2.1: North American Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.2.2: North American Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.3: European Post Herpetic Neuralgia Treatment Market
  • 4.3.1: European Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.3.2: European Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.4: APAC Post Herpetic Neuralgia Treatment Market
  • 4.4.1: APAC Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.4.2: APAC Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies
• 4.5: ROW Post Herpetic Neuralgia Treatment Market
  • 4.5.1: ROW Market by Type: Anticonvulsants, Skin Patch, and Other
  • 4.5.2: ROW Market by Application: Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Type
  • 6.1.2: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Application
  • 6.1.3: Growth Opportunities for the Global Post Herpetic Neuralgia Treatment Market by Region
• 6.2: Emerging Trends in the Global Post Herpetic Neuralgia Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Post Herpetic Neuralgia Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Post Herpetic Neuralgia Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Pfizer
• 7.2: Arbor Pharma
• 7.3: Assertio Therapeutics
• 7.4: Endo Pharma
• 7.5: Teikoku Pharma
• 7.6: Teva
• 7.7: Mylan